Pharmaceutical inhibition of RAS overcomes cytokine mediated resistance to FLT3 inhibition in FLT3-ITD+ AML
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 76 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 76 samples: 76 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1iScience · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE241650_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1009040 and SRA study SRP456942. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 76 sample titles: 76 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7732631 D1063-10_MOLM14_RASi_Rep2
- GSM7732632 D1063-11_MOLM14_RASi_IL3_Rep1
- GSM7732633 D1063-12_MOLM14_RASi_IL3_Rep2
- GSM7732634 D1063-1_MOLM14_Untreated_Rep1
- GSM7732635 D1063-2_MOLM14_Untreated_Rep2
- GSM7732636 D1063-3_MOLM14_IL3_Rep1
- GSM7732637 D1063-4_MOLM14_IL3_Rep2
- GSM7732638 D1063-5_MOLM14_FLT3i_Rep1
- GSM7732639 D1063-6_MOLM14_FLT3i_Rep2
- GSM7732640 D1063-7_MOLM14_FLT3i_IL3_Rep1
- GSM7732641 D1063-8_MOLM14_FLT3i_IL3_Rep2
- GSM7732642 D1063-9_MOLM14_RASi_Rep1
- GSM7732643 D1091-10_ITD-18_FLT3i_IL3_Rep2
- GSM7732644 D1091-11_ITD-18_RASi_Rep2
- GSM7732645 D1091-12_ITD-18_RASi_IL3_Rep2
- GSM7732646 D1091-1_ITD-18_Untreated_Rep1
- GSM7732647 D1091-2_ITD-18_IL3_Rep1
- GSM7732648 D1091-3_ITD-18_FLT3i_Rep1
- GSM7732649 D1091-4_ITD-18_FLT3i_IL3_Rep1
- GSM7732650 D1091-5_ITD-18_RASi_Rep1
- GSM7732651 D1091-6_ITD-18_RASi_IL3_Rep1
- GSM7732652 D1091-7_ITD-18_Untreated_Rep2
- GSM7732653 D1091-8_ITD-18_IL3_Rep2
- GSM7732654 D1091-9_ITD-18_FLT3i_Rep2
- GSM7732655 D929-1_MV411_Untreated_Rep1
- GSM7732656 D929-2_MV411_Untreated_Rep2
- GSM7732657 D929-3_MV411_FLT3i_Rep1
- GSM7732658 D929-4_MV411_FLT3i_Rep2
- GSM7732659 P1137_MV411_cFOS_ChIP_FLT3i_Rep1
- GSM7732660 P1137_MV411_cFOS_ChIP_Untreated_Rep1
- GSM7732661 P1383_MV411_cFOS_ChIP_FLT3i_Rep2
- GSM7732662 P1383_MV411_cFOS_ChIP_Untreated_Rep2
- GSM7732663 P1482_MOLM14_RUNX1_ChIP_EmptyVector
- GSM7732664 P1482_MOLM14_RUNX1_ChIP_FLT3i
- GSM7732665 P1482_MOLM14_RUNX1_ChIP_FLT3i_IL3
- GSM7732666 P1482_MOLM14_RUNX1_ChIP_RAS_iDAB
- GSM7732667 P1482_MOLM14_RUNX1_ChIP_Untreated
- GSM7732668 D552_ITD-15
- GSM7732669 D578_ITD-15_FLT3i
- GSM7732670 D631_ITD-16_FLT3i
+ 36 more — browse all 76 samples with per-sample file links →
- GSE338135 NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib 75 samples shares flt3, ras, aml
- GSE324062 RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance 61 samples shares flt3, ras, resistance
- GSE185651 Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1 mediated cell-intrinsic resistance 28 samples shares ras, inhibition, resistance
- GSE288707 CDK12/13 inhibition in NSCLC cell lines with acquired resistance to sotorasib 24 samples shares ras, inhibition, resistance
- GSE310675 CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer 12 samples shares ras, inhibition, resistance
- GSE289713 Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations 11 samples shares flt3, aml
- GSE319092 Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like Cells 135 samples shares aml, inhibition
- GSE245969 EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells 122 samples shares ras, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.